Li Jun-Xia, Fei Xiao-Ming, Lu Hua, Hu Hui-Jin, Li Jian-Yong
Department of Hematology, Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1204-8.
This study was aimed to investigate the effect of proteasome inhibitor bortezomib on the migration ability and hepatocyte growth factor (HGF) expression of bone marrow mesenchymal stem cells (MSC) in multiple myeloma patients. Transwell assay was employed to measure the migration ability of bone marrow MSC in vitro before and after treatment with bortezomib. The HGF mRNA expression level was determined by real-time quantitative PCR. The results indicated that after treated with bortezomib of concentrations of 2.5 nmol/L for 48 hours, the migration activity of MSC decreased significantly as compared with control cohorts (p < 0.05). The HGF mRNA level in MSC after bortezomib treatment was significantly lower than that of control group (p < 0.05). It is concluded that bortezomib can inhibit the migration and down-regulate HGF mRNA expression of bone marrow MSC in multiple myeloma patients.
本研究旨在探讨蛋白酶体抑制剂硼替佐米对多发性骨髓瘤患者骨髓间充质干细胞（MSC）迁移能力及肝细胞生长因子（HGF）表达的影响。采用Transwell实验检测硼替佐米处理前后体外骨髓MSC的迁移能力。通过实时定量PCR测定HGF mRNA表达水平。结果表明，用浓度为2.5 nmol/L的硼替佐米处理48小时后，与对照组相比，MSC的迁移活性显著降低（p<0.05）。硼替佐米处理后MSC中的HGF mRNA水平显著低于对照组（p<0.05）。结论是硼替佐米可抑制多发性骨髓瘤患者骨髓MSC的迁移并下调其HGF mRNA表达。
